Ayurcann Holdings Past Earnings Performance

Past criteria checks 0/6

Ayurcann Holdings's earnings have been declining at an average annual rate of -46.8%, while the Pharmaceuticals industry saw earnings growing at 45.6% annually. Revenues have been growing at an average rate of 42.7% per year.

Key information

-46.8%

Earnings growth rate

-34.0%

EPS growth rate

Pharmaceuticals Industry Growth23.1%
Revenue growth rate42.7%
Return on equity-2,309.9%
Net Margin-15.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Even With A 88% Surge, Cautious Investors Are Not Rewarding Ayurcann Holdings Corp.'s (CSE:AYUR) Performance Completely

Jun 28
Even With A 88% Surge, Cautious Investors Are Not Rewarding Ayurcann Holdings Corp.'s (CSE:AYUR) Performance Completely

Not Many Are Piling Into Ayurcann Holdings Corp. (CSE:AYUR) Stock Yet As It Plummets 33%

May 11
Not Many Are Piling Into Ayurcann Holdings Corp. (CSE:AYUR) Stock Yet As It Plummets 33%

Market Cool On Ayurcann Holdings Corp.'s (CSE:AYUR) Revenues Pushing Shares 29% Lower

Mar 22
Market Cool On Ayurcann Holdings Corp.'s (CSE:AYUR) Revenues Pushing Shares 29% Lower

Revenue & Expenses Breakdown

How Ayurcann Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CNSX:AYUR Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2427-4110
30 Jun 2425-4110
31 Mar 2423-4110
31 Dec 2320-5110
30 Sep 2317-590
30 Jun 2312-590
31 Mar 2310-570
31 Dec 2210-460
30 Sep 2210-460
30 Jun 229-360
31 Mar 2210040
31 Dec 2110040
30 Sep 219030
30 Jun 218020
31 Mar 216-120
30 Jun 201-100
30 Jun 190-110

Quality Earnings: AYUR is currently unprofitable.

Growing Profit Margin: AYUR is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AYUR is unprofitable, and losses have increased over the past 5 years at a rate of 46.8% per year.

Accelerating Growth: Unable to compare AYUR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AYUR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).


Return on Equity

High ROE: AYUR has a negative Return on Equity (-2309.87%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 07:27
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ayurcann Holdings Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Siddharth RajeevFundamental Research Corp.